Abstracts tagged "systemic sclerosis and treatment"

Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Ami A. Shah¹, Elena Schiopu², Soumya Chatterjee³, Mary Ellen Csuka⁴, Tracy Frech⁵, Avram Goldberg⁶, Robert F. Spiera⁷, Stanford L. Peng⁸ and Virginia D. Steen⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁵Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Benaroya Research Institute/Virginia Mason, Seattle, WA, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…
Abstract Number: 1693 • 2014 ACR/ARHP Annual Meeting
Progressive Disease in Systemic Sclerosis after One Year of Follow-up; Results of a Standardized Multidisciplinary Health Care Program
Jessica Meijs¹, Anne Schouffoer², Nina Ajmone Marsan³, Lucia Kroft⁴, Maarten K. Ninaber⁵, T.W.J. Huizinga¹ and Jeska K. De Vries-Bouwstra¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of this study is to evaluate disease course of systemic sclerosis (SSc) patients participating in a single centre multidisciplinary health-care program over…
Abstract Number: 1674 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy of Rituximab in Systemic Sclerosis
Javier Narváez¹, Juan Jose Alegre Sancho², Ivan Castellvi³, Susana Herrera⁴, Maria Molina Molina⁵, Diego Castillo⁶, Isabel de la Morena Barrio², Montserrat Robustillo Villarino², Angels Martínez Ferrer², Desamparados Ybañez García², Elia Valls Pascual², Josep Maria LLobet³, Francisca Gil Latorre⁴ and Joan Miquel Nolla⁷, ¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Dr Peset, Valencia, Spain, ⁵Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Pneumology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: It has been proved in several studies with a small number of patients that Rituximab (RTX) can prevent worsening of interstitial lung disease (ILD)…
Abstract Number: 728 • 2014 ACR/ARHP Annual Meeting
Prediction and Impact of Attacks of Raynaud’s Phenomenon, As Judged By Patient perception
Michael Hughes¹, Amir Snapir², Jack Wilkinson³, Daniel Snapir², Fredrick M. Wigley⁴ and Ariane Herrick¹, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Orion Corporation Orion Pharma, Turku, Finland, ³Research and Development, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Our aim was to evaluate (a) whether subjects with Raynaud's phenomenon (RP) can predict RP attacks because if so, then this could have implications…
Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Jessica K. Gordon³, Paula Lauto⁴ and Virginia D. Steen⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
Abstract Number: 2583 • 2013 ACR/ARHP Annual Meeting
Long-Term Treatment With Endothelin Receptor Antagonist Increases Peripheral Blood Perfusion In Systemic Sclerosis Patients
Maurizio Cutolo¹, Barbara Ruaro², Elena Bernero², Francesca Ravera³, Giuseppe Zampogna³, Elisa Alessandri², Vanessa Smith⁴ and Alberto Sulli³, ¹Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive impairment of the microvascular system and decrease of peripheral blood perfusion (PBP) (1-3). The vasoactive peptide endothelin-1…
Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Niamh P. Quillinan¹, Deirdre McIntosh², Syed Haq² and Christopher P. Denton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Daval International Ltd, Eastbourne, East Sussex, United Kingdom
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…
Abstract Number: 695 • 2012 ACR/ARHP Annual Meeting
Comparison of Intense Pulsed Light and Laser Treatment of Telangiectases in Systemic Sclerosis
Graham Dinsdale¹, Andrea Murray¹, Tonia Moore², Janice E. Ferguson³, Holly Ennis⁴, Christopher E.M Griffiths⁵ and Ariane Herrick⁶, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom, ³Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ⁴School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ⁵Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁶Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom
Background/Purpose: Cutaneous telangiectases commonly occur in systemic sclerosis (SSc) and are distressing for the patient due to their perceived unsightly appearance. The current standard treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].